We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

BN Brachyury and Radiation in Chordoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03595228
Recruitment Status : Completed
First Posted : July 23, 2018
Last Update Posted : February 28, 2022
Information provided by (Responsible Party):
Bavarian Nordic

Brief Summary:
The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity will be needed to proceed to stage 2.

Condition or disease Intervention/treatment Phase
Chordoma Biological: BN-Brachyury plus radiation Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Actual Study Start Date : October 31, 2018
Actual Primary Completion Date : December 10, 2021
Actual Study Completion Date : January 25, 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Chordoma

Arm Intervention/treatment
Experimental: BN-Brachyury plus radiation
MVA-BN-Brachyury then treatment of the tumor(s) with radiation followed by FPV-Brachyury
Biological: BN-Brachyury plus radiation
MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.

Primary Outcome Measures :
  1. Clinically Meaningful Objective Response Rate [ Time Frame: 27 months ]
    Objective response rate anytime within 12 months post completion of radiation on target lesion(s) based on RECIST 1.1

Secondary Outcome Measures :
  1. Safety of BN-Brachyury: adverse events [ Time Frame: 42 months ]
    Incidence of treatment-emergent adverse events

  2. Clinical Benefit of BN-Brachyury plus radiation therapy [ Time Frame: 42 months ]
    Evaluate other clinical endpoints that might be indicative of clinical benefits (PFS, improvement of other clinical symptoms)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed chordoma
  • Patients must have measurable disease by RECIST 1.1
  • Patients must be scheduled to have radiation therapy to at least 1 target lesion.
  • Age ≥12 years
  • Patients must have normal organ and marrow function
  • Must have recovered completely from any reversible toxicity associated with recent therapy.
  • There should be a minimum of 2 weeks from any chemotherapy, small molecule/targeted therapy, immunotherapy and/or radiation prior to enrolment
  • Females of childbearing potential and male partners of Females of childbearing potential must agree to use effective birth control or abstinence from screening to after the last vaccination therapy

Exclusion Criteria:

  • Concurrent treatment for cancer, with specific exceptions noted in the inclusion criteria
  • Chronic hepatitis B or C infection.
  • Any significant disease, that in the opinion of the investigator may impair the patient's tolerance of trial treatment.
  • Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding, or rendering of informed consent.
  • Active autoimmune diseases requiring treatment or a history of autoimmune disease that might be stimulated by vaccine treatment. This requirement is due to the potential risks of exacerbating autoimmunity.
  • Concurrent use of systemic steroids, except for physiological doses of systemic steroid replacement or local steroid use.
  • Patients who are receiving any other investigational agents within 28 days before start of trial treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to MVA-BN/FPV-Brachyury or other agents used in trial. History of allergic reactions to aminoglycoside antibiotic or egg products.
  • Serious or uncontrolled intercurrent illness, included but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with trial requirements.
  • Pregnant women are excluded from this trial due to the unknown effects of the BN-Brachyury on the fetus or infant.
  • HIV-positive patients are ineligible because of the potential for decreased immune response to the vaccine.
  • Significant cardiovascular disease, which includes but is not limited to New York Heart Association Heart Failure Class II or greater, myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03595228

Layout table for location information
United States, Arizona
Mayo Clinic, Arizona
Phoenix, Arizona, United States, 85054
United States, Florida
Mayo Clinic, Florida
Jacksonville, Florida, United States, 32224
United States, Massachusetts
Massachusetts General Hospital, Cancer Center
Boston, Massachusetts, United States, 02114
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Bavarian Nordic
Layout table for investigator information
Principal Investigator: Gregory Cote, MD Massachusetts General Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bavarian Nordic
ClinicalTrials.gov Identifier: NCT03595228    
Other Study ID Numbers: BRACHY-CHOR-001
First Posted: July 23, 2018    Key Record Dates
Last Update Posted: February 28, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type